===========================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Amendment No. 1
Under the Securities Exchange Act of 1934
ARIAD PHARMACEUTICALS, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
- ---------------------------------------------------------------------------
(Title of Class of Securities)
04033A 10 0
-----------------
(CUSIP Number)
===========================================================================
Page 1 of 9
Exhibit Index is located at page 9
<PAGE> 2
CUSIP No. 04033A 10 0
- ---------------------------------------------------------------------------
1) Name of Reporting Person and its Hoechst Marion Roussel, Inc.
I.R.S. Identification Number 44-0565557
- ---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
- ---------------------------------------------------------------------------
3) SEC Use Only
- ---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
- ---------------------------------------------------------------------------
5) Sole Voting Power 3,004,436
Number of ____________________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 3,004,436
Person With ____________________________________________________________
8) Shared Dispositive Power 0
- ---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 3,004,436
by Each Reporting Person
- ---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- ---------------------------------------------------------------------------
11) Percent of Class Represented 12.10%
by Amount in Row (9)
- ---------------------------------------------------------------------------
12) Type of Reporting Person CO
- ---------------------------------------------------------------------------
<PAGE> 3
CUSIP No. 04033A 10 0 13G
- ---------------------------------------------------------------------------
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
- ---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
- ---------------------------------------------------------------------------
3) SEC Use Only
- ---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
- ---------------------------------------------------------------------------
5) Sole Voting Power 3,004,436
Number of ____________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 3,004,436
Person With ____________________________________________________________
8) Shared Dispositive Power 0
- ---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 3,004,436
by Each Reporting Person
- ---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- ---------------------------------------------------------------------------
11) Percent of Class Represented 12.10%
by Amount in Row (9)
- ---------------------------------------------------------------------------
12) Type of Reporting Person CO
- ---------------------------------------------------------------------------
<PAGE> 4
CUSIP No. 04033A 10 0 13G
This Amendment No. 1 to the Statement on Schedule 13G of Hoechst Marion
Roussel, Inc., a Delaware corporation, and HMR Pharma, Inc., a Delaware
corporation, is filed to report the acquisition of an additional 478,120 shares
of Series B Convertible Preferred Stock of Ariad Pharmaceuticals, Inc. (the
"Issuer"). The Statement on Schedule 13G is hereby amended to read as follows:
ITEM 1(a). NAME OF ISSUER:
- ---------- ---------------
Ariad Pharmaceuticals Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
- ---------- ------------------------------------------------
26 Landsdowne Street
Cambridge, MA 02139
ITEM 2(a). NAME OF PERSON FILING:
- ---------- ----------------------
Hoechst Marion Roussel, Inc.
HMR Pharma, Inc.
Hoechst Marion Roussel, Inc., the record owner of the
securities to which this Schedule relates, is owned
98.2% by HMR Pharma, Inc., and 1.8% by Hoechst Marion
Roussel, S.A., a French corporation, both of which are
wholly-owned subsidiaries of Hoechst Marion Roussel
Aktiengesellschaft, a German corporation ("HMR AG"),
which itself is a wholly-owned subsidiary of Hoechst
Aktiengesellschaft, a publicly-held German corporation
("Hoechst AG"). Hoechst AG and HMR AG disclaim
beneficial ownership of securities held by HMRI.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
- ---------- ------------------------------------------------------------
Hoechst Marion Roussel, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
ITEM 2(c). CITIZENSHIP:
- ---------- ------------
Delaware As To Both Hoechst Marion Roussel, Inc. And
HMR Pharma, Inc.
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
- ---------- -----------------------------
Common Stock, $.001 Par Value
<PAGE> 5
CUSIP No. 04033A 10 0 13G
ITEM 2(e): CUSIP NUMBER:
- ---------- -------------
04033A 10 0
ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b) OR
13D-2(b) or (c):
- ------- -------------------------------------------------------
Not Applicable
ITEM 4. OWNERSHIP
- ------- ---------
(a): AMOUNT BENEFICIALLY OWNED:
As Of 01/01/99 3,004,436 Shares Of Series B Convertible
Preferred Stock. The Shares Are Convertible Into Common
Stock On A Share-For-Share Basis.
(b): PERCENT OF CLASS:
12.10%
(c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 3,004,436
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the 3,004,436
disposition of:
(iv) Shared power to dispose or to direct the 0
disposition of:
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
- ------- ---------------------------------------------
Not Applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
- ------- ----------------------------------------------------------------
Not Applicable
<PAGE> 6
CUSIP No. 04033A 10 0 13G
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
- ------- ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
---------------------------------------------------------------
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
- ------- ---------------------------------------------------------
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
- ------- -------------------------------
Not Applicable
ITEM 10. CERTIFICATION.
- -------- --------------
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in
connection with or as a participant in any transaction
having that purpose or effect.
<PAGE> 7
CUSIP No. 04033A 10 0 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
May 6, 1999
---------------------------------
(Date)
HMR PHARMA, INC.
/s/ Rebecca R. Tilden
---------------------------------
(Signature)
Rebecca R. Tilden
Vice President and Secretary
---------------------------------
(Name/Title)
<PAGE> 8
CUSIP No. 04033A 10 0 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
May 6, 1999
---------------------------------
(Date)
HOECHST MARION ROUSSEL, INC.
/s/ Rebecca R. Tilden
---------------------------------
(Signature)
Rebecca R. Tilden
Vice President and Secretary
---------------------------------
(Name/Title)
<PAGE> 9
CUSIP No. 04033A 10 0 13G
EXHIBIT INDEX
Exhibit No. Description Page No.
- ----------- ------------ ---------
99.A Agreement to File Jointly dated March
17, 1998, by and between Hoechst Marion
Roussel, Inc. and HMR Pharma, Inc.
(Incorporated by reference to the
Statement on Schedule 13G filed by
Hoechst Marion Roussel, Inc. and HMR
Pharma, Inc. on March 31, 1998).
